Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07363577
PHASE3

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

Sponsor: LB Pharmaceuticals Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.

Official title: A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB 102 in the Treatment of Adult Patients With Acute Schizophrenia

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

456

Start Date

2026-03

Completion Date

2027-10

Last Updated

2026-01-23

Healthy Volunteers

No

Conditions

Interventions

DRUG

LB-102 (50 mg tablet)

LB-102 oral tablet given for six weeks

DRUG

LB-102 (100 mg tablet)

LB-102 oral tablet given for six weeks

OTHER

Placebo

Placebo tablet given orally for six weeks